← Back to Patent Explorer
US5366869A Expired / Lapsed US ⏱️ 0.0 years remaining

Multiple coagulation test device and method

Assignee: COAGULATION SCIENCES LLC
•
Filing: 1991-11-08
•
Granted: 1994-11-22
•
Expires: 2011-11-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A multiple coagulation test device has a plurality of tubes, each tube having associated coagulation detection means, and containing a treatment dosage of a coagulation enhancing agent. Whole blood samples are placed in the tubes which are mixed and warmed to 37° C., with the time to coagulation determined. The agent giving the lowest clotting time is selected as the most effective treatment for reducing hemorrhaging within a few minutes and the selected treatment begun. Utilizing the inventive device eliminates the need to use a multiple agent approach, by identifying the most effective course of action.

Inventors

  • 👤 Sheldon Goldstein

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 03:46
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/483; G01N33/487; G01N33/49; G01N33/4905; C; C12; C12Q; C12Q1/00; C12Q1/56; Y; Y10; Y10T; Y10T436/00; Y10T436/10; Y10T436/106664

Claims Analysis

Total Claims: 10
Claim 1
Independent Claim 90 words
A method for determining the treatment required to arrest hemorrhaging in a patient comprising a) providing a series of different agents capable of enhancing blood clotting; b) obtaining a series of samples of the patient's blood; c) mixing a sample of blood with each of the individual agents to prepare a series of mixtures, each mixture of said series containing a different agent; d) simultaneously measuring the clotting time for each mixture in said series; and e) selecting the agent in said series which produces the most rapid clotting time.
Claim 2
Independent Claim 90 words
A method for determining the treatment required to arrest hemorrhaging in a patient comprising a) providing a series of different agents capable of enhancing blood clotting; b) obtaining a series of samples of the patient's blood; c) mixing a sample of blood with each of the individual agents to prepare a series of mixtures, each mixture of said series containing a different agent; d) simultaneously measuring the clotting time for each mixture in said series; and e) selecting the agent in said series which produces the most rapid clotting time.
Claim 3
Dependent Claim 41 words
The method of claim 1 wherein the blood clotting enhancing agent is selected from the group consisting of coagulation factors, platelets, plasminogen activator, desmopressin acetate (DDAVP), epsilo-amino caproic acid, protamine, aprotinin, fibronectin, thrombin, plasminogen, plasma, a cryoprecipitated plasma product and prostacyclin.
Claim 4
Dependent Claim 40 words
The method of claim 2 wherein the coagulation factor is coagulation factor I (fibrinogen), Ia (fibrin), II (prothrombin), IIa (thrombin), III (thromboplastin), IV, V, VI, VII, VIII, IX, X, XI, XII, VIII:C, von Willebrand factor or a bovine coagulation factor.
Claim 5
Dependent Claim 16 words
The method of claim 2 wherein the plasma is bovine plasma, or human fresh frozen plasma.
Claim 6
Independent Claim 102 words
A method for arresting hemorrhaging in a patient comprising a) providing a series of different agents capable of enhancing blood clotting; b) obtaining a series of samples of the patient's blood; c) mixing a sample of blood with each of the individual agents to prepare a series of mixtures, each mixture of said series containing a different agent; d) simultaneously measuring the clotting time for each mixture in said series; e) selecting the agent in said series which produces the most rapid clotting time; and f) administering a blood clotting effective amount of the selected agent from step e) to the patient.
Claim 7
Independent Claim 102 words
A method for arresting hemorrhaging in a patient comprising a) providing a series of different agents capable of enhancing blood clotting; b) obtaining a series of samples of the patient's blood; c) mixing a sample of blood with each of the individual agents to prepare a series of mixtures, each mixture of said series containing a different agent; d) simultaneously measuring the clotting time for each mixture in said series; e) selecting the agent in said series which produces the most rapid clotting time; and f) administering a blood clotting effective amount of the selected agent from step e) to the patient.
Claim 8
Dependent Claim 41 words
The method of claim 5 wherein the blood clotting enhancing agent is selected from the group consisting of coagulation factors, platelets, plasminogen activator, desmopressin acetate (DDAVP), epsilo-amino caproic acid, protamine, aprotinin, fibronectin, thrombin, plasminogen, plasma, a cryoprecipitated plasma product and prostacyclin.
Claim 9
Dependent Claim 40 words
The method of claim 6 wherein the coagulation factor is coagulation factor I (fibrinogen), Ia (fibrin), II (prothrombin), IIa (thrombin), III (thromboplastin) IV, V, VI, VII, VIII, IX, X, XI, XII, VIII:C, von Willebrand factor or a bovine coagulation factor.
Claim 10
Dependent Claim 16 words
The method of claim 6 wherein the plasma is bovine fresh frozen plasma, or human plasma.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1997-11-21 1998-05-23 1998-11-22 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2001-11-21 2002-05-23 2002-11-22 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2005-11-21 2006-05-23 2006-11-22 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag